304 related articles for article (PubMed ID: 28624108)
61. Clinical insights for cancer outcomes in renal transplant patients.
Alberú J
Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
[TBL] [Abstract][Full Text] [Related]
62. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
63. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation.
Nava F; Cappelli G; Mori G; Granito M; Magnoni G; Botta C; Solazzo A; Fontana F; Baisi A; Bonucchi D
Transplant Proc; 2014 Sep; 46(7):2263-8. PubMed ID: 25242766
[TBL] [Abstract][Full Text] [Related]
64. Calcineurin inhibitor minimization in pediatric liver allograft recipients.
Dell-Olio D; Kelly DA
Pediatr Transplant; 2009 Sep; 13(6):670-81. PubMed ID: 19413716
[TBL] [Abstract][Full Text] [Related]
65. Calcineurin inhibitor-free protocols: risks and benefits.
Barbari AG; Stephan AG; Masri MA
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):1-23. PubMed ID: 17237886
[TBL] [Abstract][Full Text] [Related]
66. [Immunosuppression in liver transplantation: renoprotective regimens].
Serrano Aulló MT; Parra Moncasi E; Lorente Pérez S
Gastroenterol Hepatol; 2011; 34(6):422-7. PubMed ID: 21458889
[TBL] [Abstract][Full Text] [Related]
67. Immunosuppressive minimization with mTOR inhibitors and belatacept.
Diekmann F
Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
[TBL] [Abstract][Full Text] [Related]
68. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.
Karie-Guigues S; Janus N; Saliba F; Dumortier J; Duvoux C; Calmus Y; Lorho R; Deray G; Launay-Vacher V; Pageaux GP
Liver Transpl; 2009 Sep; 15(9):1083-91. PubMed ID: 19718632
[TBL] [Abstract][Full Text] [Related]
69. Different in vitro proliferation and cytokine-production inhibition of memory T-cell subsets after calcineurin and mammalian target of rapamycin inhibitors treatment.
Merino D; San Segundo D; Medina JM; Rodrigo E; Asensio E; Irure J; Fernández-Fresnedo G; Arias MA; López-Hoyos M
Immunology; 2016 Jun; 148(2):206-15. PubMed ID: 26931075
[TBL] [Abstract][Full Text] [Related]
70. Calcineurin inhibitor-free immunosuppression in kidney transplantation.
Guerra G; Srinivas TR; Meier-Kriesche HU
Transpl Int; 2007 Oct; 20(10):813-27. PubMed ID: 17645419
[TBL] [Abstract][Full Text] [Related]
71. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation.
Créput C; Blandin F; Deroure B; Roche B; Saliba F; Charpentier B; Samuel D; Durrbach A
Liver Transpl; 2007 Jul; 13(7):1004-10. PubMed ID: 17600361
[TBL] [Abstract][Full Text] [Related]
72. Everolimus immunosuppression in kidney transplantation: What is the optimal strategy?
Witzke O; Sommerer C; Arns W
Transplant Rev (Orlando); 2016 Jan; 30(1):3-12. PubMed ID: 26603484
[TBL] [Abstract][Full Text] [Related]
73. Immunosuppression minimization vs. complete drug withdrawal in liver transplantation.
Londoño MC; Rimola A; O'Grady J; Sanchez-Fueyo A
J Hepatol; 2013 Oct; 59(4):872-9. PubMed ID: 23578883
[TBL] [Abstract][Full Text] [Related]
74. Experience with belatacept rescue therapy in kidney transplant recipients.
Brakemeier S; Kannenkeril D; Dürr M; Braun T; Bachmann F; Schmidt D; Wiesener M; Budde K
Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
[TBL] [Abstract][Full Text] [Related]
75. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
76. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
Zeier M; Van Der Giet M
Transpl Int; 2011 Jan; 24(1):30-42. PubMed ID: 20642495
[TBL] [Abstract][Full Text] [Related]
77. Safety of mTOR inhibitors in adult solid organ transplantation.
Ventura-Aguiar P; Campistol JM; Diekmann F
Expert Opin Drug Saf; 2016; 15(3):303-19. PubMed ID: 26667069
[TBL] [Abstract][Full Text] [Related]
78. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
79. The MANDELA study: A multicenter, randomized, open-label, parallel group trial to refine the use of everolimus after heart transplantation.
Deuse T; Bara C; Barten MJ; Hirt SW; Doesch AO; Knosalla C; Grinninger C; Stypmann J; Garbade J; Wimmer P; May C; Porstner M; Schulz U
Contemp Clin Trials; 2015 Nov; 45(Pt B):356-363. PubMed ID: 26363128
[TBL] [Abstract][Full Text] [Related]
80. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J
Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
